Also trades as: NAMSW (NASDAQ) · $vol 0M
NAMS NASDAQ
NewAmsterdam Pharma Company N.V.
1W: +1.9%
1M: -4.8%
3M: +1.7%
YTD: -14.2%
1Y: +29.2%
3Y: +154.2%
5Y: +211.2%
$27.98
-2.24 (-7.41%)
Weekly Expected Move ±8.8%
$24
$27
$30
$32
$35
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.3B
52W Range21.135-42.205
Volume890,462
Avg Volume1,305,675
Beta0.08
Dividend—
Analyst Ratings
Company Info
CEOMichael Davidson
Employees100
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-09
Websitenewamsterdampharma.com
Gooimeer 2-35
Naarden, NH 1411 DC
NL
Naarden, NH 1411 DC
NL
31 35 206 2971
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimerâs disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest News
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma reports Q1 results
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kooij Louise Frederi | M-Exempt | 25,000 | $11.90 | 2026-07-20 |
| Kooij Louise Frederi | M-Exempt | 80,000 | $11.17 | 2026-07-20 |
| Kooij Louise Frederi | S-Sale | 70,200 | $29.96 | 2026-07-20 |
| Kooij Louise Frederi | S-Sale | 31,885 | $31.05 | 2026-07-20 |
| Kooij Louise Frederi | S-Sale | 2,915 | $31.71 | 2026-07-20 |